SELLAS Life Sciences (SLS) Current Assets (2010 - 2026)

SELLAS Life Sciences (SLS) has 17 years of Current Assets data on file, last reported at $111.2 million in Q1 2026.

• Quarterly Current Assets rose 247.7% year-over-year to $111.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $111.2 million (up 247.7% YoY) and the FY2025 annual result came in at $75.2 million, up 360.65% from the prior year.
• Current Assets advanced to $111.2 million in Q1 2026 per SLS's latest filing, from $75.2 million in the prior quarter.
• Across five years, Current Assets topped out at $111.2 million in Q1 2026 and bottomed at $3.2 million in Q4 2023.
• The 5-year median for Current Assets is $22.6 million (2022), against an average of $29.9 million.
• The widest annual swing landed in 2023, when Current Assets tumbled 82.14%; it then jumped 414.72% in 2024.
• Tracing SLS's Current Assets over 5 years: stood at $17.8 million in 2022, then sank by 82.14% to $3.2 million in 2023, then jumped by 414.72% to $16.3 million in 2024, then jumped by 360.65% to $75.2 million in 2025, then jumped by 47.81% to $111.2 million in 2026.
• Per Business Quant, the three latest SLS Current Assets figures stand at $111.2 million (Q1 2026), $75.2 million (Q4 2025), and $49.1 million (Q3 2025).

Peer Comparison